Alzheimer's Disease & Dementia
An Introduction to Alzheimer's Disease & Dementia
Major advances in the understanding of the pathogenesis of Alzheimer’s disease (AD), the most common form of dementia, have occurred over recent years, but the need for truly disease-modifying therapies remains. Novel pharmacotherapy strategies under investigation include the repurposing of medications used to treat non-AD illnesses and multi-target-directed ligands, offering promise in this challenging treatment landscape.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Alzheimer's Disease & Dementia Content
Jeffrey Cummings, AAIC 2020 – Microbiome in Alzheimer’s Disease
Valued editorial board member Jeffrey Cummings (University of Nevada, Las Vegas [UNLV], and Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) shares exciting insights from the session he co-chaired at AAIC20 entitled ‘Microbiome in Alzheimer’s Disease: Pathogenesis and Treatment Implications’. Questions 1. Could you give us a brief overview of the role of […]
Bengt Winblad, EAN 2020 – Emerging therapeutic targets for Alzheimer’s disease
Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including emerging therapeutic targets for Alzheimer’s disease (AD) and the role of the FKBP51-Hsp90 complex in underlying pathophysiological processes. Questions 1. What are the most promising emerging therapeutic targets […]
Bengt Winblad, EAN 2020 – Targeting Beta-amyloid for the Treatment of Early Alzheimer’s
Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including the recent resurrection of an investigational human monoclonal antibody targeting beta-amyloid for the treatment of early Alzheimer’s disease (AD). Question What is your opinion of the resurrection of […]
Bengt Winblad, EAN 2020 – Overview of the MOPEAD Project
Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including the MOPEAD initiative. MOPEAD (Models of Patient Engagement for Alzheimer’s disease), aims to deliver a step-change in AD patient engagement strategies and a paradigm shift from late-stage diagnosis […]
Bengt Winblad, EAN 2019 – Ageing and dementia
We had the great opportunity to chat with our valued European editorial board member Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden) at EAN 2019. We covered aspects of ageing and dementia that were highlighted across various presentations he was involved with at the congress. Questions 1. What have studies of the dicarboxylate […]
Bart de Strooper, EAN 2019 – Brain Prize Lecture
Prof. Claudio Bassetti, President Elect of EAN, met with Prof. Bart de Strooper winner of the Lundbeck Foundation’s Brain Prize to talk about his work and his Brain Prize lecture at EAN 2019 – The prodromal, cellular phase of Alzheimer’s Disease: towards a novel understanding of the disorder. Video produced by and shared with kind […]
What to expect at INS 2019
Timothy Deer, President of the International Neuromodulation Society (INS), on how the attending global neuromodulation community at INS 2019 is set to experience a meaningful and unforgettable event. The International Neuromodulation Society’s 14th World Congress will be held in Sydney, Australia on 25–30 May 2019. Source: This video was produced by the INS and is shared […]
Jeffrey Cummings, AAN 2019 – Emerging Alzheimer therapies and considerations for future research
US Neurology Editorial Board member, Jeffrey Cummings (UNVL Department of Brain Health and Cleveland Clinic Lou Ruvo Center for Brain Health, California, USA), considers both successes and failures with emerging new treatments for Alzheimer’s disease, and important steps to be taken to improve future clinical trial design. Questions 1. What is the current status […]
Molecular Pathogenesis of Alzheimer’s Disease
US Neurology. 2019;15(1):14–6.
Alzheimer’s disease was first described in 1906, and yet we have still not fully elucidated the pathogenesis of the condition. It is known that the disease is characterized by the polymerization of amyloid β-peptide (Aβ), leading to the formation of plaques.1,2 The cascade of events initiated by Aβ polymerization eventually leads to progressive neurodegeneration and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!